Regenerative medicine is poised for continued expansion in 2020, after the latest global industry briefing reveals another year of significant growth, and total global financings the second highest yet.
Released at Biotech Showcase last week, the Alliance for Regenerative Medicine (ARM)’s State of the Industry presentation showed the US$9.8B of total global financing in 2019 was attributed to gene-based therapies, cell therapies, and tissue engineering.
Financing remains strong across venture capital and partnerships, with M&A activity showcasing large and middle cap pharma’s interest in the cell and gene therapy space.
The pipeline is robust, with several next-generation technologies entering the clinic, and an increase in clinical trials for indications with large patient populations. As at the end of 2019, there were a recorded 1,066 clinical trials underway, with 58 per cent of phase 1 trials in gene-modified cell therapies.
Considerable effort and progress in addressing various manufacturing challenges are being made, with in-house manufacturing capabilities becoming a strategic priority, companies investing in manufacturing earlier in the development process, and CMOs becoming attractive acquisition targets.
AusBiotech is a member of ARM, an international community of over 350 small and large companies, non-profit research institutions, patient organisations, and other sector stakeholders dedicated to realising the promise of regenerative medicine for patients around the world.
Read the full State of the Industry presentation here.